美国中年人群非酒精性脂肪肝病及脂肪性肝炎患病率的前瞻性评估
这项前瞻性研究在835名无症状中年美国人中,采用磁共振PDFF和肝活检评估NAFLD/NASH患病率。最终664人符合标准,NAFLD患病率为38%(95%CI 34-41%),NASH为14%(95%CI 12-17%),显著纤维化(F≥2)为5.9%(95%CI 4-8%)。
要点
- 无症状中年美国人中NAFLD患病率高达38%,NASH为14%。
- 显著纤维化(F≥2)见于5.9%的无症状个体,桥接纤维化为1.6%。
- NASH相关因素包括种族、肥胖和糖尿病。
核心结论
- 在该无症状中年美国人群中,NAFLD总体患病率为38%,经活检证实的NASH患病率为14%。
研究设计与样本
- 前瞻性队列研究,纳入835名接受结肠镜检查的无症状中年人,最终664人符合纳入排除标准。
- 采用磁共振PDFF(LMS-PDFF)和瞬时弹性成像(FibroScan)筛查NAFLD,异常者接受肝活检,由2位专家病理学家盲法判读。
主要发现
- NAFLD患病率为38%(95%CI 34-41%),NASH患病率为14%(95%CI 12-17%)。
- 活检显示无肝硬化,显著纤维化(F≥2)占5.9%(95%CI 4-8%),桥接纤维化占1.6%(95%CI 1-3%)。
- 多变量分析显示与NASH相关的因素为种族、肥胖和糖尿病。
关键数值与推荐
- NAFLD定义为PDFF≥5%或组织学诊断NAFLD;NASH由活检定义。
- 平均年龄56±6.4岁,男性50%,平均BMI 30.48±5.46 kg/m2,肥胖者占52%。
临床怎么用
- 在无症状中年人群中应重视NAFLD/NASH筛查,尤其合并肥胖、糖尿病者。
- 影像学联合活检可准确评估NAFLD/NASH患病率及纤维化程度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Large prospective studies to establish the prevalence of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively assessed the prevalence and severity of NAFLD/NASH in a cohort of asymptomatic middle-aged Americans attending a colonoscopy class at a gastroenterology clinic. METHODS: Screening for NAFLD was performed using magnetic resonance (MR)-based LiverMultiScan® proton density fat fraction (LMS-PDFF). MR exams also included corrected T1 and elastography for liver stiffness measurement (LSM). FibroScan® was also used to measure LSM. Participants with predetermined abnormal imaging parameters were offered a liver biopsy. Biopsies were read in a blinded fashion with results based on the consensus by 2 expert pathologists. The prevalence of NAFLD was determined by PDFF ≥5% or by histological diagnosis of NAFLD (if biopsy data were available). The prevalence of NASH was defined by biopsy. RESULTS: Of 835 participants, 664 met the inclusion and exclusion criteria. The mean age was 56 ± 6.4 years, 50% were male, the mean BMI was 30.48 ± 5.46 kg/m2, and 52% were obese. The prevalence of NAFLD was 38% (95% CI 34-41%) and the prevalence of NASH was 14% (95% CI 12-17%). While no patient had cirrhosis on biopsy, significant fibrosis (F ≥2) was present in 5.9% (95% CI 4-8%) and bridging fibrosis in 1.6% (95% CI 1-3%). In a multivariable analysis, factors associated with the presence of NASH were race, obesity, and diabetes. CONCLUSION: Using state-of-the-art liver imaging modalities and reference biopsy, this study establishes an overall prevalence of NAFLD of 38% and NASH by biopsy of 14% in this cohort of asymptomatic middle-aged US adults. LAY SUMMARY: There are no prospective studies to determine how common is nonalcoholic steatohepatitis (NASH), the severe form of non-alcoholic fatty liver disease (NAFLD). In a large number of asymptomatic middle-aged Americans, we used a combination of state-of-the-art liver imaging methods and liver biopsy to prospectively determine the prevalence of NAFLD and NASH. NAFLD was diagnosed in 38%, NASH in 14%, and significant liver fibrosis in 6% of asymptomatic middle-aged Americans.
引用
- Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021. PMID: 33746083. doi:10.1016/j.jhep.2021.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。